World Journal of Nephrology and Urology, ISSN 1927-1239 print, 1927-1247 online, Open Access
Article copyright, the authors; Journal compilation copyright, World J Nephrol Urol and Elmer Press Inc
Journal website http://www.wjnu.org

Original Article

Volume 1, Number 2-3, June 2012, pages 51-58


Factors Associated With Fibrate-Induced Creatinine Elevation: Observations in an Outpatient Setting

Figure

Figure 1.
Figure 1. Mean change in creatinine seen within significantly associated factors.

Tables

Table 1. Pre and Post-Fibrate Treatment Creatinine Values Amongst Patients Stratified by Different Characteristics
 
Pre Treatement Creatinine (µmol/L)Post Treatement Creatinine (µmol/L)Paired t test
nMeansdMin / MaxMedianMeansdMin / MaxMedianP
Total13281.917.333 / 12783.093.820.452 / 14391.00.0001
Male9285.717.233 / 12785.599.619.070 / 14397.00.0001
Female4073.214.135 / 10673.580.517.252 / 12882.00.0026
Diabetic3482.114.159 / 12185.089.218.053 / 13988.00.0004
Non-Diabetic9781.918.433 / 12783.095.421.152 / 14393.00.0001
On statin treatment5880.616.833 / 11782.090.416.853 / 14187.50.0001
Not on statin treatment7483.017.733 / 12783.096.522.652 / 14393.00.0001

 

Table 2. Model 1: Association Between Change in Creatinine Concentration (Dependent Variable) and Baseline Factors (Independent Variable) Studied Using Separate Linear Regression Analyses; Model 2: Multiple Regression Analysis With Change in Creatinine (Dependent Variable) and Changes in Lipid Values (Independent Variables). Analysis Corrected for Duration of Fibrate Treatement
 
FactorNcoefficient95% Confidence IntervalP
Model 1
  Male1326.641.0 / 12.30.022
  Pre treatement Creatinine132-0.20-0.3 / -0.10.011
  Age1290.04-0.3 / 0.20.782
  Diabetes131-6.37-12.4 / -0.40.037
  Duration of treatment1241.70-6.5 / 3.10.482
  Statin treatment132-3.78-9.1 / 1.50.16
Model 2
  Change in TC levels1090.54-1.68 / 2.770.63
  Change in TG levels109-1.37-2.43 / -0.32-0.011
  Change in HDL-C levels109-6.53-6.30 / 19.360.32